Bayer stock weighs the September 14 court date
Published on 08/24/2026 at 09:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bayer stock moved into a legal countdown as the company faces a September 14 glyphosate hearing, with second-quarter 2026 revenue rising 2.2 percent to EUR 10.872 billion and adjusted EBITDA increasing 1.9 percent to EUR 2.144 billion. Bayer (DE000BAY0017) also kept full-year guidance at EUR 44.7 billion to EUR 46.7 billion in revenue and core EPS of EUR 4.20 to EUR 4.70.
Legal calendar drives the setup
The hearing date matters because it keeps the Roundup overhang attached to a stock that closed Friday at EUR 47.90, down 0.9 percent, yet still up 29 percent year to date. The shares also stood 2.8 percent higher over the past month and 11 percent below the 52-week high of EUR 53.86.
That split between legal risk and operating progress is visible in the second-quarter numbers. Crop Science posted revenue growth of 3.5 percent to EUR 4.910 billion and adjusted EBITDA growth of 30.2 percent to EUR 902 million, while Pharma delivered 0.8 percent revenue growth to EUR 4.458 billion and adjusted EBITDA of EUR 1.055 billion.
Debt target moved lower
Bayer tightened its deleveraging plan in the same earnings release, now targeting net financial debt of EUR 29 billion to EUR 30 billion by the end of 2026, down from EUR 32 billion to EUR 33 billion before. The change follows the Apollo transaction, which includes a EUR 3.0 billion equity injection into a new contraceptive-business entity and is slated to close in the third quarter.
Jefferies kept a Hold rating with a EUR 46 price target on August 10, while other houses turned more constructive after the quarterly figures. That gap leaves the stock trading close to one skeptical view and still below the levels implied by the most upbeat calls.
Pipeline adds support
Pharma also has fresh program updates, including acceptance in China for Aflibercept 8 mg in macular edema following retinal vein occlusion and new Phase III data scheduled for the ESC Congress 2026. Partner MustGrow Biologics also received its first milestone payment from Bayer, a small but concrete sign of movement in the biologics pipeline.
Herbicide business remains central
The product most closely tied to the market's current concern is Roundup, the herbicide brand at the center of the glyphosate litigation. The court date now functions as a visible test of whether Bayer can turn better quarterly execution and a lower debt target into a cleaner valuation story.
Shares near key levels
At EUR 47.90 on Friday, the stock sat between the recent recovery and the 52-week peak. The next decisive move still depends more on the courtroom than on the tape.
Fact box
Company: Bayer AG
ISIN: DE000BAY0017
Ticker: BAYN
Exchange: Xetra
Price (as of August 23, 2026): EUR 47.90
Market cap: EUR 46.8 billion
Sector / Industry: Health Care / Pharmaceuticals
Index membership: DAX, Euro Stoxx 50
Read more
